Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2008 1
2010 2
2011 2
2012 1
2014 2
2015 2
2016 3
2017 2
2018 2
2019 4
2020 1
2021 5
2022 3
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean zeng qi yan (5 results)?
Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.
Loh AHP, Thura M, Gupta A, Tan SH, Kuan KKY, Ang KH, Merchant K, Chang KTE, Yon HY, Chen Y, Cheng MHW, Mahadev A, Ng MCH, Seng MS, Iyer P, Chia PL, Soh SY, Zeng Q. Loh AHP, et al. Among authors: zeng q. Mol Ther Oncolytics. 2023 Aug 18;30:153-166. doi: 10.1016/j.omto.2023.08.006. eCollection 2023 Sep 21. Mol Ther Oncolytics. 2023. PMID: 37674627 Free PMC article.
Hexa-Branched Nanographenes with Large Two-Photon Absorption.
Zhao XJ, Ju YY, Su YM, Tang C, Zeng Q, Feng L, Wang C, Müllen K, Tan YZ. Zhao XJ, et al. Among authors: zeng q. J Am Chem Soc. 2023 Sep 6;145(35):19333-19337. doi: 10.1021/jacs.3c05662. Epub 2023 Aug 28. J Am Chem Soc. 2023. PMID: 37638550
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.
Chee CE, Ooi M, Lee SC, Sundar R, Heong V, Yong WP, Ng CH, Wong A, Lim JSJ, Tan DSP, Soo R, Tan JTC, Yang S, Thura M, Al-Aidaroos AQ, Chng WJ, Zeng Q, Goh BC. Chee CE, et al. Among authors: zeng q. Target Oncol. 2023 May;18(3):391-402. doi: 10.1007/s11523-023-00962-w. Epub 2023 Apr 15. Target Oncol. 2023. PMID: 37060431 Free PMC article. Clinical Trial.
Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q. Thura M, et al. Among authors: zeng q. Nat Commun. 2021 Nov 2;12(1):6431. doi: 10.1038/s41467-021-26548-6. Nat Commun. 2021. PMID: 34728638 Free PMC article. No abstract available.
33 results